[go: up one dir, main page]

WO2008125714A1 - Utilisation de la l-carnitine pour le traitement de l'hypertension artérielle - Google Patents

Utilisation de la l-carnitine pour le traitement de l'hypertension artérielle Download PDF

Info

Publication number
WO2008125714A1
WO2008125714A1 PCT/ES2008/000249 ES2008000249W WO2008125714A1 WO 2008125714 A1 WO2008125714 A1 WO 2008125714A1 ES 2008000249 W ES2008000249 W ES 2008000249W WO 2008125714 A1 WO2008125714 A1 WO 2008125714A1
Authority
WO
WIPO (PCT)
Prior art keywords
carnitine
arterial hypertension
treatment
group
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2008/000249
Other languages
English (en)
Spanish (es)
Inventor
Alfonso Mate Barrero
Carmen María VÁZQUEZ CUETO
José Luis MIGUEL CARRASCO
Lucía GÓMEZ AMORES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Sevilla
Original Assignee
Universidad de Sevilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Sevilla filed Critical Universidad de Sevilla
Publication of WO2008125714A1 publication Critical patent/WO2008125714A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the use of L-carnitine for the preparation of a medicament or a nutritional supplement for the treatment or control of arterial hypertension.
  • this invention also refers to pharmaceutical compositions for the treatment of said pathology that comprise a therapeutically effective amount of L-carnitine.
  • L-Carnitine (L-3-hydroxy-4-N, N, N-trimethyllaminobutyrate) is an amino acid derivative present in most animal species and in many microorganisms and plants. It is widely distributed throughout the body, although it occurs in greater amounts in the heart and skeletal muscle (Panter RA and Mudd JB (1969). FEBS Lett. 5 (2): 169-170; Rebouche CJ (1992) FASEB J. 6 (15): 3379-3386.).
  • this amino acid derivative consists in acting as a cofactor in the transport of fatty acids inside the mitochondria, where the ⁇ -oxidation of the same occurs, for the obtaining of metabolic energy (Bremer J. (1983). Physiol Rev. 63 (4): 1420-1480.), Playing a crucial role in the metabolism of fatty acids.
  • Acute and chronic myocardial ischemia angina pectoris, sequelae of myocardial infarction, heart failure, senile heart, congestive heart disease, arrhythmias, etc.
  • treatment with L-carnitine helps to alleviate the symptoms produced by the lack thereof.
  • treatment with L-carnitine improves the recovery of patients, relieving symptoms, reducing the requirement of other drugs and reducing mortality.
  • EBPOC chronic obstructive broncho-pulmonary disease
  • emphysema DaI Negro R., et al (1988). Int. J. Clin. Pharmacol. Ther. Toxicol. 26 (5): 269-272; Montgomery SA, et al (2003). Int. Clin. Psychopharmacol. 18 (2): 61-71); in senile dementia (Bella R., et al (1990). Int. J. Clin. Pharmacol. Res. 10 (6): 355-360.); in some cases of patients with ataxia (Gallagher C, et al L. (2002). J. Child Neurol.
  • L-Carnitine performs a control function on arterial hypertension, which may constitute a nutritional supplement that helps control said pathology, as well as being used together with others antihypertensives, as an adjuvant for greater control of arterial hypertension.
  • L-carnitine could be used as a functional product, as a supplement in the diet or through the use of pharmaceutical forms, to help control arterial hypertension. It could be said that the consumption of L-carnitine could not be a substitute for those medications aimed at reducing blood pressure, as well as hygienic-dietary measures to improve blood pressure levels, however, its use either alone or in combination with other antihypertensive therapies, could perform an adjuvant effect to control blood pressure, given its hypotensive or anti-hypertensive effect. To all this should be added the low toxicity that L-carnitine has, as well as the lack of side effects, which makes it a perfect candidate as a supplement to apply in hypertensive people.
  • a first aspect of the invention relates to the use of L-carnitine for the preparation of a medicament for the treatment of arterial hypertension.
  • a second aspect of the invention relates to the use of L-camitin as an adjuvant in a pharmaceutical composition for the treatment of arterial hypertension.
  • a third aspect of the invention relates to the use of L-carnitine for the preparation of a nutritional supplement for the treatment or control of arterial hypertension.
  • a fourth aspect of the invention relates to a pharmaceutical composition for the treatment of arterial hypertension comprising L-carnitine in a therapeutically effective amount.
  • the pharmaceutical composition also comprises other agents for the treatment of arterial hypertension or antihypertensives.
  • Figure 1 shows the analysis of the diastolic pressure (mm Hg) for rats that have been treated with 300 mg / kg L-carnitine.
  • Column A represents a group of normotensive rats not treated with L-carnitine
  • column B a group of hypertensive rats not treated with L-carnitine
  • column C a group of normotensive rats treated with L-carnitine
  • column D a hypertensive rats treated with L-carnitine.
  • Figure 2 shows the analysis of systolic pressure (mm Hg) for rats that have been treated with 300 mg / kg L-carnitine.
  • Column A represents a group of normotensive rats not treated with L-carnitine
  • column B a group of hypertensive rats not treated with L-carnitine
  • column C a group of normotensive rats treated with L-carnitine
  • column D a hypertensive rats treated with L-carnitine.
  • the invention was carried out using hypertensive and normotensive rats aged between 20-22 weeks. At this age, hypertensive rats have continuous and sustained hypertension.
  • Four experimental groups of animals were performed:
  • Group A normotensive rats not treated with L-carnitine.
  • Group C normotensive rats treated with L-carnitine.
  • the treatment with L-carnitine consisted of administering 300 mg of L-carnitine / Kg of body weight in drinking water for a period of 12 weeks. Once this time has elapsed, we measure the systolic and diastolic blood pressure. The results obtained were:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de la L-carnitine pour l'élaboration d'un médicament ou d'un complément nutritionnel pour le traitement ou la régulation de l'hypertension artérielle. De la même manière, l'invention concerne des compositions pharmaceutiques pour le traitement de ladite pathologie qui comprennent une dose efficace sur le plan thérapeutique de L-carnitine.
PCT/ES2008/000249 2007-04-16 2008-04-15 Utilisation de la l-carnitine pour le traitement de l'hypertension artérielle Ceased WO2008125714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200701091 2007-04-16
ES200701091A ES2306610B1 (es) 2007-04-16 2007-04-16 Uso de la l-carnitina para el tratamiento de la hipertension arterial.

Publications (1)

Publication Number Publication Date
WO2008125714A1 true WO2008125714A1 (fr) 2008-10-23

Family

ID=39863300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2008/000249 Ceased WO2008125714A1 (fr) 2007-04-16 2008-04-15 Utilisation de la l-carnitine pour le traitement de l'hypertension artérielle

Country Status (2)

Country Link
ES (1) ES2306610B1 (fr)
WO (1) WO2008125714A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632619C1 (ru) * 2016-04-20 2017-10-06 Владимир Павлович Лобко Способ лечения больных артериальной гипертонией

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351753B1 (es) * 2009-07-07 2011-09-29 Universidad De Sevilla Uso de la l-carnitina para la prevencion y tratamiento del daño cardiaco inflamatorio asociado a la hipertension arterial.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599232A (en) * 1983-02-16 1986-07-08 Sigma Tau Industrie Faramaceutiche Riunite S.P.A. Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy
WO2000027386A1 (fr) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Procede d'utilisation de la l-carnitine de propionyle pour fabriquer un medicament destine a inhiber la proliferation des cellules musculaires lisses
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599232A (en) * 1983-02-16 1986-07-08 Sigma Tau Industrie Faramaceutiche Riunite S.P.A. Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy
WO2000027386A1 (fr) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Procede d'utilisation de la l-carnitine de propionyle pour fabriquer un medicament destine a inhiber la proliferation des cellules musculaires lisses
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALVAREZ DE SOTOMAYOR M. ET AL.: "L-Carnitine and its propionate: Improvements of endothelial function in SHR through superoxide dismutase-dependent mechanisms", FREE RADICAL RESEARCH, vol. 41, no. 8, August 2007 (2007-08-01), pages 884 - 891 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632619C1 (ru) * 2016-04-20 2017-10-06 Владимир Павлович Лобко Способ лечения больных артериальной гипертонией

Also Published As

Publication number Publication date
ES2306610A1 (es) 2008-11-01
ES2306610B1 (es) 2009-09-11

Similar Documents

Publication Publication Date Title
ES2832506T3 (es) Composiciones que comprenden ribósido de nicotinamida y una urolitina
ES2433476T3 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
US20100305206A9 (en) Modulation of nitric oxide synthases by betaines
ES2487647T3 (es) Composición de combinación que comprende, como ingrediente activo, L-carnitina o propionil-L-carnitina, para la prevención o el tratamiento de la insuficiencia venosa crónica
BR112019012476A2 (pt) composições de aminoácido e métodos para o tratamento de doenças e distúrbios musculares
IL286592B2 (en) Amino acid compounds for the treatment of liver disease
ES2393534T3 (es) Uso de composiciones basadas en aminoácidos para el tratamiento de la sarcopenia
WO2019246221A1 (fr) Compositions et procédés pour le traitement de maladies et troubles hépatiques
US20160303177A1 (en) Nutritional supplement
US9572848B1 (en) Composition of matter for sexual dysfunction
BR112020023132A2 (pt) composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
RU2582962C1 (ru) Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)
US20160303176A1 (en) Nutritional supplement
ES2306610B1 (es) Uso de la l-carnitina para el tratamiento de la hipertension arterial.
ES2219633T3 (es) Sal de creatina que tiene eficacia nutricional y terapeutica y composiciones que la contienen.
ES2606200T3 (es) Composición farmacéutica para su uso en el tratamiento o prevención de deficiencias vitamínicas y minerales en pacientes que han sido sometidos a una cirugía de baipás gástrico
CN116348104A (zh) 用于软骨退行性变的使用橄榄苦苷和槲皮素的组合的组合物和方法
US20130065823A1 (en) Supplement for Strengthening the Muscles of a Human
FI3694505T3 (fi) Yhdiste ja koostumus käytettäväksi sellaisten keskushermoston sairauksien ennaltaehkäisevään ja/tai parantavaan hoitoon, jotka ovat tunnettuja neuronaalisen plastisuuden vähenemisestä, erityisesti tunnettuja synaptisen plastisuuden vähenemisestä
Guta Is taurine a pharmaconutrient
ITMI20131028A1 (it) Arginina e/o citrullina per uso nel trattamento e/o nella prevenzione dell'artrosi
ES2676529T3 (es) Composición útil para el tratamiento de la diabetes tipo 2
ITMI20002666A1 (it) Formulazioni alimentari ad elevato contenuto di calcio
CA3106895A1 (fr) Compositions nutritionnelles pour l'amelioration de la performance musculaire
ES2804649B2 (es) Composición hipoleptinémica y su uso

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08761496

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08761496

Country of ref document: EP

Kind code of ref document: A1